Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 11, 2008, Pages 1884-1891

  Develter, J ^a   Booth, N A ^b   Declerck, P J ^a   Gils, Ann ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Diabody; Fibrinolysis; PAI 1; TAF1

Indexed keywords

HETERODIMER; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 33H1F7; MONOCLONAL ANTIBODY T12D11; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BLOOD CLOT LYSIS; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; INHIBITION KINETICS; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; THROMBOCYTE FREE PLASMA;

ANTIBODIES, MONOCLONAL; CARBOXYPEPTIDASE U; CLONING, MOLECULAR; DIMERIZATION; DRUG DELIVERY SYSTEMS; FIBRINOLYSIS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOSIS;

EID: 54149103468     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03137.x     Document Type: Article

References (40)

1. Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij CL, van Zonneveld AJ, van Moerik JA. Endothelial plasminogen activator inhibitor (PAI): A new member of the Serpin gene family. EMBO J 1986; 5: 2539-44.
2. Lijnen HR, Collen D. Mechanisms of physiological fibrinolysis. Baillieres Clin Haematol 1995; 8: 277-90.
3. Kruithof EK, Tran Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-13.
4. Thorsen S, Philips M, Selmer J, Lecander I, Astedt B. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type.1 and type.2. Eur J Biochem 1988; 175: 33-9.
5. Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-7.
6. Declerck PJ, De Mol M, Vaughan DE, Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. J Biol Chem 1992; 267: 11693-6.
7. Urano T, Strandberg L, Johansson LB, Ny T. A substrate-like form of plasminogen-activator-inhibitor type.1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem 1992; 209: 985-92.
8. Munch M, Heegaard CW, Andreasen PA. Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Biochim Biophys Acta 1993; 1202: 29-37.
9. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
10. Fleury V, Angles-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: The role of carboxy-terminal lysines. Biochemistry 1991; 30: 7630-8.
11. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
12. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45.
13. Silveira A, Schatteman K, Goossens F, Moor E, Scharpe S, Stromqvist M, Hamsten A. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-8.
14. van-Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
15. Gils A, Declerck PJ. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb Haemost 2004; 91: 425-37.
16. Leurs J, Hendriks D. Carboxypeptidase.U (TAFIa): A metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease. Thromb Haemost 2005; 94: 471-87.
17. Wang YX, Zhao L, Nagashima M, Vincelette J, Sukovich D, Li W, Subramanyam B, Yuan S, Emayan K, Islam I, Hrvatin P, Bryant J, Light DR, Vergona R, Morser J, Buckman BO. A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) - part I: pharmacological characterization. Thromb Haemost 2007; 97: 45-53.
18. Gils A, Ceresa E, Macovei AM, Marx PF, Peeters M, Compernolle G, Declerck PJ. Modulation of TAFI function through different pathways-implications for the development of TAFI inhibitors. J Thromb Haemost 2005; 3: 2745-53.
19. Binette TM, Taylor FB Jr, Peer G, Bajzar L. Thrombin-thrombomodulin connects coagulation and fibrinolysis: More than an in.vitro phenomenon. Blood 2007; 110: 3168-75.
20. Gils A, Alessi MC, Brouwers E, Peeters M, Marx P, Leurs J, Bouma B, Hendriks D, Juhan-Vague I, Declerck PJ. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23: 1122-7.
21. Debrock S, Declerck PJ. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: Identification of two different mechanisms. Biochim Biophys Acta 1997; 1337: 257-66.
22. Cochlovius B, Kipriyanov SM, Stassar MJ, Christ O, Schuhmacher J, Strauss G, Moldenhauer G, Little M. Treatment of human B cell lymphoma xenografts with a CD3 × CD19 diabody and T cells. J Immunol 2000; 165: 888-95.
23. Verbeke K, Gils A, Declerck PJ. Inhibition of plasminogen activator inhibitor-1: Antibody fragments and their unique sequences as a tool for the development of profibrinolytic drugs. J Thromb Haemost 2004; 2: 298-305.
24. Mosnier LO, von-dem-Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
25. Verheijen JH, Chang GT, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost 1984; 51: 392-5.
26. Mutch NJ, Thomas L, Moore NR, Lisiak KM, Booth NA. TAFIa, PAI-1 and alpha-antiplasmin: Complementary roles in regulating lysis of thrombi and plasma clots. J Thromb Haemost 2007; 5: 812-17.
27. Kipriyanov SM, Moldenhauer G, Martin AC, Kupriyanova OA, Little M. Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng 1997; 10: 445-53.
28. Bothmann H, Pluckthun A. Selection for a periplasmic factor improving phage display and functional periplasmic expression. Nat Biotechnol 1998; 16: 376-80.
29. Robbie LA, Young SP, Bennett B, Booth NA. Thrombi formed in a Chandler loop mimic human arterial thrombi in structure and pai. 1 content and distribution. Thromb Haemost 1997; 77: 510-15.
30. Berry CN, Lunven C, Lechaire I, Girardot C, O'Connor SE. Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type.1 in rat models of venous and arterial thrombosis. Br J Pharmacol 1998; 125: 29-34.
31. Morange PE, Juhan-Vague I, Scarabin PY, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, PRIME Study group. Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. Thromb Haemost 2003; 89: 554-60.
32. Nagashima M, Werner M, Wang M, Zhao L, Light DR, Pagila R, Morser J, Verhallen P. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 2000; 98: 333-42.
33. Minnema MC, Friederich PW, Levi M, dem-Borne PA, Mosnier LO, Meijers JC, Biemond BJ, Hack CE, Bouma BN, ten Cate H. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101: 10-14.
34. Wang YX, da Cunha V, Vincelette J, Zhao L, Nagashima M, Kawai K, Yuan S, Emayan K, Islam I, Hosoya J, Sullivan ME, Dole WP, Morser J, Buckman BO, Vergona R. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: Enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost 2007; 97: 54-61.
35. Kipriyanov SM, Le Gall F. Recent advances in the generation of bispecific antibodies for tumor immunotherapy. Curr Opin Drug Discov Dev 2004; 7: 233-42.
36. Holliger P, Prospero T, Winter G. 'Diabodies': Small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90: 6444-8.
37. Perisic O, Webb PA, Holliger P, Winter G, Williams RL. Crystal structure of a diabody, a bivalent antibody fragment. Structure 1994; 2: 1217-26.
38. Armstrong PW, Collen D. Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part.2. Circulation 2001; 103: 2987-92.
39. Bode C, Runge MS, Branscomb EE, Newell JB, Matsueda GR, Haber E. Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator. J Biol Chem 1989; 264: 944-8.
40. Kurokawa T, Iwasa S, Kakinuma A, Stassen JM, Lijnen HR, Collen D. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator. Thromb Haemost 1991; 66: 684-93.